Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.06.19
Views: 804

Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK

Dr Angela Lamarca speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the results of the ABC-06 clinical trial.

She explains that this was a randomised phase III trial for patients with biliary tract cancer (ABC) who had previously been treated with cisplatin plus gemcitabine chemotherapy (CisGem). The aim of the study was to determine whether there was benefit from second line oxaliplatin plus 5-FU chemotherapy (ASC mFOLFOX).

Dr Lamarca concludes that the trial indicated there was a benefit to this second-line chemotherapy, that the treatment was tolerable and that she believes this should be the new standard of care for suitable patients.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation